Clovis Oncology, Inc. (CLVS) News

Clovis Oncology, Inc. (CLVS): $0.67

0.00 (0.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLVS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 393

in industry

Filter CLVS News Items

CLVS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CLVS News Highlights

  • For CLVS, its 30 day story count is now at 14.
  • Over the past 15 days, the trend for CLVS's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
  • The most mentioned tickers in articles about CLVS are BEAT, DECK and DRUG.

Latest CLVS News From Around the Web

Below are the latest news stories about Clovis Oncology Inc that investors may wish to consider to help them evaluate CLVS as an investment opportunity.

Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting

BOULDER, Colo., February 25, 2022--LuMIERE TiP at SNMMI mid-Winter and ACNM meeting curtain raiser news release

Yahoo | February 25, 2022

Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Yahoo | February 24, 2022

Clovis Oncology GAAP EPS of -$0.50, revenue of $35.97M

Clovis Oncology press release (NASDAQ:CLVS): Q4 GAAP EPS of -$0.50. Revenue of $35.97M (-16.9% Y/Y). “We have been looking forward to 2022 for a long time, which we anticipate will be the most significant year for clinical data read-outs in the Company’s history,” said Patrick J. Mahaffy, President and CEO of...

Seeking Alpha | February 23, 2022

Clovis Oncology, Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Clovis Oncology, Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 23, 2022

Recap: Clovis Oncology Q4 Earnings

Clovis Oncology (NASDAQ: CLVS ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Clovis Oncology beat estimated earnings by 14.29%, reporting an EPS of $-0.48 versus Full story available on Benzinga.com

Benzinga | February 23, 2022

Clovis Oncology quarterly net loss narrows even as product revenue declines (CLVS)

Clovis Oncology (CLVS) saw its net loss narrow ~19% in Q4 2021 compared to the prior-year period even as revenue declined.

Seeking Alpha | February 23, 2022

Clovis Oncology''s (CLVS) CEO Patrick Mahaffy on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 23, 2022

Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones

BOULDER, Colo., February 23, 2022--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook.

Yahoo | February 23, 2022

Clovis Oncology Q4 2021 Earnings Preview

Clovis Oncology (NASDAQ:CLVS) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, before market open.The consensus EPS Estimate is -$0.50 (+51.0% Y/Y) and

Seeking Alpha | February 22, 2022

Clovis Oncology Inc. (NASDAQ: CLVS) Stock Forecast 2022: Profitable With Bullish Signals

In the last trading session, 2.53 million shares of the Clovis Oncology Inc. (NASDAQ:CLVS) were traded, and its beta was 1.70. Most recently the company’s share price was $1.81, and it changed around -$0.09 or -4.74% from the last close, which brings the market valuation of the company to $241.49M. CLVS currently trades at a … Clovis Oncology Inc. (NASDAQ: CLVS) Stock Forecast 2022: Profitable With Bullish Signals Read More »

Marketing Sentinel | February 15, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6116 seconds.